AIM AMEX
AIM ImmunoTech Inc.
1W: -4.9%
1M: -22.9%
3M: -39.1%
YTD: -84.8%
1Y: -92.8%
3Y: -99.6%
5Y: -99.9%
$0.18
-0.01 (-4.10%)
Weekly Expected Move ±7.6%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
31 relationships31
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2021-04-07
Earliest Filing
2026-03-06
Latest Filing
partner: 21
customer: 4
target: 3
supplier: 2
investor: 1
Counterparties (Filed by AIM)
31 relationshipsCompanies named in AIM's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Maxim Group LLC | MMS | partner | Appointed as exclusive dealer-manager for the Rights Offering | 2026-03-06 | View |
| Broadridge Corporate Issuer Solutions, LLC | — | partner | Appointed as Subscription Agent and Information Agent for the Rights Offering | 2026-03-06 | View |
| AIM ImmunoTech Inc. | AIM | target | Issuer of the Promissory Note in the Note Purchase Agreement | 2025-11-19 | View |
| Streeterville Capital, LLC | — | investor | Investor purchasing the Promissory Note | 2025-11-19 | View |
| AIM ImmunoTech Inc. | AIM | partner | Company issuing shares in equity distribution | 2025-04-04 | View |
| Maxim Group LLC | MMS | partner | Sales agent for the equity distribution | 2025-04-04 | View |
| Maxim Group LLC | MMS | partner | Placement agent for the securities offering | 2024-10-01 | View |
| AIM ImmunoTech Inc. | AIM | target | Company issuing securities in the placement | 2024-10-01 | View |
| Maxim Group LLC | MMS | partner | Placement agent for the securities offering | 2024-06-03 | View |
| AIM ImmunoTech Inc. | AIM | target | Company issuing securities in the placement | 2024-06-03 | View |
| AIM IMMUNOTECH, INC. | AIM | partner | Provider of Ampligen® and confidential information for research projects | 2023-09-29 | View |
| Roswell Park Cancer Institute CORPORATION | — | partner | Conducts research projects utilizing AIM's Ampligen® and confidential information | 2023-09-29 | View |
| Erasmus University Medical Center Rotterdam | — | partner | University medical center partnering for pancreatic cancer immune monitoring research project | 2023-04-07 | View |
| AIM ImmunoTech Inc. | AIM | partner | Biotech company granting unrestricted funds for research project | 2023-04-07 | View |
| AstraZeneca | AZN | partner | Partner in clinical research agreement to evaluate Ampligen in combination with Imfinzi for pancreatic cancer treatment | 2023-01-17 | View |
| Erasmus MC | — | partner | Partner conducting investigator-initiated clinical study (DURIPANC) combining Ampligen and durvalumab | 2023-01-17 | View |
| AIM Immunotech Inc. | AIM | partner | Tenant in a lease agreement for leased premises at the New Jersey Bioscience Center | 2022-06-21 | View |
| New Jersey Economic Development Authority | — | partner | Landlord in a lease agreement for leased premises at the New Jersey Bioscience Center | 2022-06-21 | View |
| AIM ImmunoTech Inc | AIM | customer | Sponsor of the Phase II clinical trial for Ampligen in Post-COVID conditions. | 2022-06-17 | View |
| Amarex Clinical Research, LLC | — | supplier | Provider of trial services including project management, data management, and clinical monitoring. | 2022-06-17 | View |
| Open Orphan plc | ORPH | partner | Parent company of hVIVO and provider of clinical research services | 2021-09-30 | View |
| hVIVO | — | partner | Clinical trial partner conducting the Phase 2a Human Challenge Trial | 2021-09-30 | View |
| hVIVO Services Limited | — | partner | AIM ImmunoTech Inc. executed a Reservation and Start-Up Agreement with hVIVO Services Limited to reserve space in a UK q | 2021-07-13 | View |
| Shenzhen Smoore Technology Limited | — | partner | Partnered to develop and test a new inhalation delivery device for Ampligen | 2021-05-27 | View |
| Smoore International Holdings Limited | — | partner | Parent company of Shenzhen Smoore Technology Limited | 2021-05-27 | View |
| Branford Auctions, LLC | — | customer | Purchasing obsolete equipment and machinery from AIM ImmunoTech Inc. | 2021-04-23 | View |
| Perry Videx LLC | — | customer | Purchasing obsolete equipment and machinery from AIM ImmunoTech Inc. | 2021-04-23 | View |
| Phoenix Equipment Corporation | — | customer | Purchasing obsolete equipment and machinery from AIM ImmunoTech Inc. | 2021-04-23 | View |
| Roswell Park Comprehensive Cancer Center | — | partner | Entered into a material transfer and research agreement for pre-clinical testing of Ampligen. | 2021-04-19 | View |
| University of Cagliari | — | partner | Material Transfer and Research Agreement for drug Ampligen research | 2021-04-07 | View |
| Polysciences Inc. | — | supplier | Agreement for manufacture of AIM's polynucleotides and test methods | 2021-04-07 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-14 | Material Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-09-10 | Material Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-09-04 | Material Agreement; Termination of Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-08-11 | Regulation FD; Exhibits | View | |
| 2026-08-10 | Earnings Release; Exhibits | View | |
| 2026-08-06 | Material Agreement; Exhibits | Agreement | View |
| 2026-08-05 | Termination of Agreement | View | |
| 2026-07-16 | Shareholder Vote | View | |
| 2026-06-15 | Other Events; Exhibits | View | |
| 2026-06-11 | Material Agreement; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-06-10 | Bylaws Amendment; Exhibits | View | |
| 2026-06-04 | Regulation FD; Exhibits | View | |
| 2026-05-21 | Material Agreement; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-05-19 | Material Agreement; Earnings Release; Financial Obligation; Regulation FD; Exhibits | Agreement | View |
| 2026-05-14 | Regulation FD; Exhibits | View | |
| 2026-05-12 | Unregistered Equity Sales; Exhibits | View | |
| 2026-05-08 | Material Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-04-10 | Material Agreement; Exhibits | Agreement | View |
| 2026-03-06 | Entry into Material Definitive Agreement; Material Modification to Rights of Security Holders; Amend | Agreement | View |
| 2026-02-05 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR